Elizabeth Messersmith
Keine laufenden Positionen mehr
Profil
Elizabeth Messersmith worked as the Chief Development Officer & Senior Vice President at NVN Liquidation, Inc. from 2019 to 2021.
Prior to that, she was the Senior VP-Clinical Operations & Data Management at Quark Pharmaceuticals, Inc. from 2016 to 2018.
She also held the position of Vice President-Research & Development Operations at Balance Therapeutics, Inc. Dr. Messersmith received her undergraduate and graduate degrees from the University of Kansas and her doctorate from The University of Texas Health Science Center at Houston.
Ehemalige bekannte Positionen von Elizabeth Messersmith
| Unternehmen | Position | Ende |
|---|---|---|
| NVN LIQUIDATION, INC. | Corporate Officer/Principal | 02.03.2021 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01.05.2018 |
Balance Therapeutics, Inc.
 Balance Therapeutics, Inc. BiotechnologyHealth Technology Balance Therapeutics, Inc. develops therapeutics to address conditions of intellectual disability. Its pharmacological approach, based on technology licensed from Stanford University, hypothesizes that restoring the proper balance between inhibition and excitation at the neuronal synapse by antagonizing excessive inhibitory circuits could result in the appropriate plasticity for memory and learning to occur in many conditions of intellectual disability. The company was founded by Lyndon Lien, Craig Garner and Daniel Wetmore in 2009 and is headquartered in San Bruno, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Elizabeth Messersmith
| University of Kansas | Graduate Degree |
| The University of Texas Health Science Center at Houston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NVN LIQUIDATION, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Balance Therapeutics, Inc.
Balance Therapeutics, Inc. BiotechnologyHealth Technology Balance Therapeutics, Inc. develops therapeutics to address conditions of intellectual disability. Its pharmacological approach, based on technology licensed from Stanford University, hypothesizes that restoring the proper balance between inhibition and excitation at the neuronal synapse by antagonizing excessive inhibitory circuits could result in the appropriate plasticity for memory and learning to occur in many conditions of intellectual disability. The company was founded by Lyndon Lien, Craig Garner and Daniel Wetmore in 2009 and is headquartered in San Bruno, CA. | Health Technology |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
